47
Remodeling the failing heart: : the biology and future treatment options J-L Balligand (UCL-Brussels, BE) [email protected]

the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) [email protected] ... Circ Heart

Embed Size (px)

Citation preview

Page 1: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Remodeling the failing heart: : the biology and future treatment options

J-L Balligand (UCL-Brussels, BE)

[email protected]

Page 2: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

• phenotypic plasticity : remodeling is characterized by changes in myocardial structure that happen in response to either mechanical overload or a loss of substance such as that occurring after myocardial infarction.

• Myocardial remodeling is an essential mechanism that allows for cardiac output to be maintained in the presence of chronically abnormal loading conditions or depressed contractility.

Myocardial remodeling: definitions

Page 3: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Jessup et al N Engl J Med, 2003 (review)

Page 4: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Jessup et al N Engl J Med, 2003 (review)

Page 5: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Thick Thick and dilated

Dilated Indeterminate

Normal

Patterns of LV remodeling with cardiac magnetic resonance imaging

Khouri MG et al. Circ Cardiovasc Imaging (2010) 3;164-171

Page 6: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Harding JD et al Circulation 2001

Reversal of electrical remodeling with LVAD

Page 7: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Myocyte changes

Extracellular matrix changes

Microvascular changes

Myocardial regeneration

Remodeling involves:

Page 8: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Hirsch E et al on behalf of WG Myocardial Function ESC Eur J Heart Fail (2013)

Cell-cell cross-talk

Page 9: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Cardiac myocyte

Page 10: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Physiological hypertrophy

Concentric hypertrophy

Eccentric hypertrophy

Increased expression of embryonic genes

Normal muscle cell

Growth stimuli

Apoptosis

Autophagy

Patterns of myocyte hypertrophy in myocardial remodeling

Page 11: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

dilated cardiomyopathy

Beuckelmann D et al Circulation 1992

Page 12: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 13: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Serca2a

• Gene therapy (AAV1-Serca2a) • Antagomir (miR-25) • SUMO-ylation

Page 14: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Del Monte et al Circulation 1999

Page 15: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Zsebo K…Hajjar R Circ Res 2014

Page 16: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 17: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 18: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 19: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Myofilaments

• Myosin ATPase: omecantiv mecarbil

Page 20: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Malik F et al Science 2011

Page 21: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Malik F et al Science 2011

Page 22: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Cleland JGF et al Lancet 2011

Page 23: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Circ Heart Fail. 2015 May 29. pii: CIRCHEARTFAILURE.114.002152. [Epub ahead of print]

Page 24: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 25: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Mitochondria

• Cardiolipin protection by SS peptides

Page 26: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

SS peptides protect mitochondria from oxidative damage

Page 27: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 28: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 29: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Membrane receptors

• The beta3-adrenergic receptor

Page 30: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Balligand et al. Proc Nat Acad Sci USA(1993)

β-adrenergic stimulation of NO Synthase attenuates the inotropic

effect

β1+2-adrenergic receptor blockade unveils a negative inotropic effect of

isoproterenol, a non-specific β-adrenergic agonist

Which β-adrenergic receptor ? By what mechanism ?

Gauthier et al. J Clin Invest (1996)

Page 31: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

β3 AR coupling in mammalian heart

Gauthier et al J Clin Invest 1998:102 (7): 1377 Moniotte et al Circulation 2001: 103 (12); 1649 Dessy et al Circulation 2004;110(8):948 Moniotte et al Eur J Heart Failure 2007; 9 (12): 1163 Hammond J, Balligand JL, JMCC 2012 ; 52(2): 330-340 Belge C et al. Circulation 2014; 129: 451

β3AR

Gαi

NOS

NO

sGC

cGMP

β1AR

Gαs

Effect on remodeling ? 1. hypertrophy 2. coronary vasodilatation 3. fibrosis 4. metabolism ?

Page 32: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

β3AR protects against cardiac hypertrophy PBS PE In vitro

1000

1200

1400

1600

1800

NRC

M a

era

(µm

2 )

AdV:GFP

*

Belge C*, Hammond J*, Dubois-Deruy E* et al, Circulation 2014 129, 451-62 AdV:hβ3AR

#

AdV:hβ3AR AdV:GFP

hβ3AR TG

#

hβ3AR TG

#

hβ3AR TG

#

hβ3AR TG

#

In vivo

Myo

cyte

are

a (µ

m2)

0 100 200 300 400 500 600 700

WT

*

saline Iso 50mg/kg/d

0 100 200 300 400 500 600 700

WT AngII

*

0 100 200 300 400 500 600 700

WT Iso 30mg/kg/d

*

0

250

500

750

WT

*

TAC 9weeks

Belge C et al. Circulation 2014;129:451-462

Page 33: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

β3AR

Gαi

NOS

NO

sGC

cGMP

Targets downstream NOS/cGMP

PKG

Hypertrophy

Titin-P Troponin-I-P

Myocyte/tissue elasticity Myofilament Ca++ sensitivity

Page 34: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

The cardiac fibroblast and myocyte-fibroblast cross-talk

Page 35: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

$

*

Myocardial fibrosis after TAC 9 weeks

WT TG 0

3

9

6

12

β3AR protects against myocardial fibrosis

Myocardial fibrosis after Angiotensin II infusion by minipump (14 days)

Belge C et al. Circulation 2014;129:451-462

Page 36: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Results in vitro

POTENTIAL PARACRINE FACTORS INVOLVED IN THE ANTIFIBROTIC EFFECT FROM β3-AR CARDIAC MYOCYTES TO CARDIAC FIBROBLASTS

Secretome from cardiac myocytes

B3AR

GFP PE +/-

β3 PE +/-

M. Mayr (King's College London, Cardiovascular Division) Gel-free proteomic analysis

Page 37: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N° 634559

Page 38: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Membrane receptors

• Combined AT1-R antagonist and neprilysin inhibitor: LCZ 696

Page 39: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 40: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 41: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 42: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

The endothelial cell and endothelial-myocyte cross-talk

Page 43: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

RBC

EC

CM

Close apposition of cardiac myocytes and capillary endothelial cells

Page 44: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 45: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

Lim SL et al Eur Heart J 2015

Page 46: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart
Page 47: the biology and future treatment options - European · PDF filethe biology and future treatment options . J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be ... Circ Heart

That’all

• Questions